Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis

Nino Kvirkvelia, Malgorzata McMenamin, Vanessa Iris Gutierrez, Besarion Lasareishvili, Michael P. Madaio

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Current therapies to limit kidney disease progression lack specificity and often have systemic toxicity. To approach this problem, we postulated that a human monoclonal antibody (F1.1), directed against the noncollagenous-1 domain (NC1) of α3(IV) collagen that localizes in glomeruli, could serve as a vehicle for targeted drug delivery. Given enhanced exposure of the NC1 domain of α3(IV) during glomerular diseases, with limited epitope expression in other organs, α3(IV)NC1 provides an ideal target for delivery of disease-modifying agents. As a potential disease-modifying agent, we initially took advantage of recent observations that PGE2 promoted recovery after established injury during the course of nephrotoxic nephritis. To address the general applicability of the approach, the efficacy of glomerular delivery of dexamethasone was also examined. To achieve glomerular targeted therapy, PGE2 and dexamethasone were coupled to F1.1. After confirmation of the composition and activity of the conjugates, both glomerular localization and the capacity of the conjugates to modify disease were evaluated. After injection into mice with established nephritis, resolution of disease was enhanced with both agents, with normalization of histology and improved blood urea nitrogen levels in conjugate-treated mice compared with untreated mice. The results provide a novel means of targeting glomeruli during nephritis, irrespective of cause, by providing efficient drug delivery, with the potential of limiting systemic effects.

Original languageEnglish (US)
Pages (from-to)F680-F684
JournalAmerican Journal of Physiology - Renal Physiology
Volume309
Issue number8
DOIs
StatePublished - Jan 1 2015

Fingerprint

Nephritis
Antibodies
Pharmaceutical Preparations
Dinoprostone
Dexamethasone
Blood Urea Nitrogen
Kidney Diseases
Disease Progression
Epitopes
Histology
Collagen
Monoclonal Antibodies
Injections
Wounds and Injuries
Therapeutics

Keywords

  • Antibody-drug conjugates
  • Glomeruli
  • Nephritis
  • Targeted delivery

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis. / Kvirkvelia, Nino; McMenamin, Malgorzata; Gutierrez, Vanessa Iris; Lasareishvili, Besarion; Madaio, Michael P.

In: American Journal of Physiology - Renal Physiology, Vol. 309, No. 8, 01.01.2015, p. F680-F684.

Research output: Contribution to journalArticle

Kvirkvelia, N, McMenamin, M, Gutierrez, VI, Lasareishvili, B & Madaio, MP 2015, 'Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis', American Journal of Physiology - Renal Physiology, vol. 309, no. 8, pp. F680-F684. https://doi.org/10.1152/ajprenal.00289.2015
Kvirkvelia, Nino ; McMenamin, Malgorzata ; Gutierrez, Vanessa Iris ; Lasareishvili, Besarion ; Madaio, Michael P. / Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis. In: American Journal of Physiology - Renal Physiology. 2015 ; Vol. 309, No. 8. pp. F680-F684.
@article{f590cece127441d2b6d3b7e09153bb1c,
title = "Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis",
abstract = "Current therapies to limit kidney disease progression lack specificity and often have systemic toxicity. To approach this problem, we postulated that a human monoclonal antibody (F1.1), directed against the noncollagenous-1 domain (NC1) of α3(IV) collagen that localizes in glomeruli, could serve as a vehicle for targeted drug delivery. Given enhanced exposure of the NC1 domain of α3(IV) during glomerular diseases, with limited epitope expression in other organs, α3(IV)NC1 provides an ideal target for delivery of disease-modifying agents. As a potential disease-modifying agent, we initially took advantage of recent observations that PGE2 promoted recovery after established injury during the course of nephrotoxic nephritis. To address the general applicability of the approach, the efficacy of glomerular delivery of dexamethasone was also examined. To achieve glomerular targeted therapy, PGE2 and dexamethasone were coupled to F1.1. After confirmation of the composition and activity of the conjugates, both glomerular localization and the capacity of the conjugates to modify disease were evaluated. After injection into mice with established nephritis, resolution of disease was enhanced with both agents, with normalization of histology and improved blood urea nitrogen levels in conjugate-treated mice compared with untreated mice. The results provide a novel means of targeting glomeruli during nephritis, irrespective of cause, by providing efficient drug delivery, with the potential of limiting systemic effects.",
keywords = "Antibody-drug conjugates, Glomeruli, Nephritis, Targeted delivery",
author = "Nino Kvirkvelia and Malgorzata McMenamin and Gutierrez, {Vanessa Iris} and Besarion Lasareishvili and Madaio, {Michael P.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1152/ajprenal.00289.2015",
language = "English (US)",
volume = "309",
pages = "F680--F684",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "8",

}

TY - JOUR

T1 - Human anti-α3(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis

AU - Kvirkvelia, Nino

AU - McMenamin, Malgorzata

AU - Gutierrez, Vanessa Iris

AU - Lasareishvili, Besarion

AU - Madaio, Michael P.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Current therapies to limit kidney disease progression lack specificity and often have systemic toxicity. To approach this problem, we postulated that a human monoclonal antibody (F1.1), directed against the noncollagenous-1 domain (NC1) of α3(IV) collagen that localizes in glomeruli, could serve as a vehicle for targeted drug delivery. Given enhanced exposure of the NC1 domain of α3(IV) during glomerular diseases, with limited epitope expression in other organs, α3(IV)NC1 provides an ideal target for delivery of disease-modifying agents. As a potential disease-modifying agent, we initially took advantage of recent observations that PGE2 promoted recovery after established injury during the course of nephrotoxic nephritis. To address the general applicability of the approach, the efficacy of glomerular delivery of dexamethasone was also examined. To achieve glomerular targeted therapy, PGE2 and dexamethasone were coupled to F1.1. After confirmation of the composition and activity of the conjugates, both glomerular localization and the capacity of the conjugates to modify disease were evaluated. After injection into mice with established nephritis, resolution of disease was enhanced with both agents, with normalization of histology and improved blood urea nitrogen levels in conjugate-treated mice compared with untreated mice. The results provide a novel means of targeting glomeruli during nephritis, irrespective of cause, by providing efficient drug delivery, with the potential of limiting systemic effects.

AB - Current therapies to limit kidney disease progression lack specificity and often have systemic toxicity. To approach this problem, we postulated that a human monoclonal antibody (F1.1), directed against the noncollagenous-1 domain (NC1) of α3(IV) collagen that localizes in glomeruli, could serve as a vehicle for targeted drug delivery. Given enhanced exposure of the NC1 domain of α3(IV) during glomerular diseases, with limited epitope expression in other organs, α3(IV)NC1 provides an ideal target for delivery of disease-modifying agents. As a potential disease-modifying agent, we initially took advantage of recent observations that PGE2 promoted recovery after established injury during the course of nephrotoxic nephritis. To address the general applicability of the approach, the efficacy of glomerular delivery of dexamethasone was also examined. To achieve glomerular targeted therapy, PGE2 and dexamethasone were coupled to F1.1. After confirmation of the composition and activity of the conjugates, both glomerular localization and the capacity of the conjugates to modify disease were evaluated. After injection into mice with established nephritis, resolution of disease was enhanced with both agents, with normalization of histology and improved blood urea nitrogen levels in conjugate-treated mice compared with untreated mice. The results provide a novel means of targeting glomeruli during nephritis, irrespective of cause, by providing efficient drug delivery, with the potential of limiting systemic effects.

KW - Antibody-drug conjugates

KW - Glomeruli

KW - Nephritis

KW - Targeted delivery

UR - http://www.scopus.com/inward/record.url?scp=84944472879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944472879&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00289.2015

DO - 10.1152/ajprenal.00289.2015

M3 - Article

C2 - 26290372

AN - SCOPUS:84944472879

VL - 309

SP - F680-F684

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 8

ER -